Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Status:
Withdrawn
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
Patients with a patent foramen ovale in the setting of endocardially placed cardiac
implantable electronic devices such as pacemakers, defibrillators, or resynchronization
therapies are likely at higher risk for paradoxical embolic events from device lead thrombus.
The investigators are conducting this study to determine if the anticoagulant medication
Apixaban is more effective at reducing MRI detected brain lesions compared to placebo.